American Society of Hirudotherapy

Superficial Thrombophlebitis (Saphenous Tributary)

Investigational use for superficial thrombophlebitis of saphenous tributaries (not DVT); evidence limited to small, mostly Soviet and Russian series.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for superficial thrombophlebitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
What evidence exists?
Tier C (investigational). No randomized trial of leech therapy for superficial thrombophlebitis was identified; only small, mostly Soviet and Russian clinical series (Kutakov 1965, 60 patients; Magomedov 1998, 46 patients), older observations described in books (see “What the books describe” below) and isolated case reports exist. Evidence-based therapy includes oral NSAIDs for pain, fondaparinux 2.5 mg daily for 45 days (or LMWH) for proximal saphenous involvement (CALISTO trial), graduated compression, leg elevation, and warm compresses. Duplex ultrasound is essential to assess thrombus length and rule out deep vein thrombosis or junctional extension — saphenofemoral or saphenopopliteal junction involvement requires anticoagulation.
Main risks
  • Missed or unrecognized DVT propagation (must be ruled out by duplex ultrasound first)
  • Bleeding from bite sites for 6 to 24 hours after detachment, magnified by concurrent NSAID use
  • Bruising and tenderness over the leg for 5 to 10 days
  • Local skin infection or septic thrombophlebitis if infection is present
  • Aeromonas infection (uncommon)
  • Allergic reaction to leech saliva (uncommon)
  • Triggering pulmonary embolism if DVT extension is not recognized
  • Delay or replacement of evidence-based fondaparinux when junctional involvement is present
Who should not consider this
  • Patients with deep vein thrombosis (must rule out with duplex ultrasound)
  • Patients with saphenofemoral or saphenopopliteal junction involvement (anticoagulation primary)
  • Patients with septic thrombophlebitis (antibiotics primary)
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Pregnant patients (require hematology guidance)
  • Patients with critical limb ischemia (ABI under 0.4)
What to ask your clinician
  • Has a duplex ultrasound been performed to characterize the thrombus and rule out DVT or junctional extension?
  • What is the length of the thrombus, and is anticoagulation indicated (e.g. CALISTO criteria)?
  • Have I been screened for hypercoagulable conditions if the thrombophlebitis is unprovoked or recurrent?
  • Am I a candidate for fondaparinux 2.5 mg daily for 45 days?
  • Where exactly will leeches be placed — adjacent to, NOT on, the thrombosed segment?
  • What is my plan for graduated compression and follow-up duplex?
  • What is the practitioner's experience and Aeromonas-prevention plan?
When to seek urgent care
  • Sudden shortness of breath, chest pain, cough with blood, fainting, or rapid heart rate (possible pulmonary embolism — call 911)
  • New unilateral leg swelling, severe pain extending into the deep system, or red warm area (DVT propagation)
  • Fever, chills, or severe pain along the vein (septic thrombophlebitis)
  • Spreading red streaks up the leg (lymphangitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Severe leg pain, coldness, or pallor (acute arterial event)
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for superficial thrombophlebitis.
  • Small clinical series without randomization do NOT establish efficacy versus fondaparinux or NSAIDs.
  • Mechanism rationale (decongestion, anti-inflammation) does NOT replace anticoagulation when junctional involvement is present.
  • Leech therapy must NEVER be applied without first ruling out DVT and junctional extension via duplex.
  • Leech therapy is not a substitute for evidence-based fondaparinux, NSAIDs, or compression.

Clinical Profile

Category
Vascular
ICD-10
I80.00, I80.01, I80.02, I80.03, I80.10, I80.20, I80.3
Safety tier
Medium

Evidence Summary

Superficial thrombophlebitis (typically of a saphenous tributary) is conventionally managed with NSAIDs, fondaparinux or LMWH (especially for proximal disease >5 cm), warm compresses, and compression, with duplex ultrasound required to exclude DVT propagation. No randomized trial of leech therapy for superficial thrombophlebitis was identified in PubMed, Europe PMC or ClinicalTrials.gov. Small clinical series exist, mostly Soviet and Russian, as summarised by Baskova and Isakhanyan (2004): Kutakov (1965, Klin Med; 60 patients with lower-limb thrombophlebitis, concluding that leeches may be usable in the subacute stage but not in chronic disease) and Magomedov (1998; 46 patients with acute lower-limb thrombophlebitis, 26 given leeches plus standard care versus 20 given standard care alone, with a shorter hospital stay in the leech group; how patients were allocated is not described). The monograph also retells older reports of treated patients without a comparison group (for example Ternier 1922 and Blumental 1936; see “What the books describe” below). A case report describes leech therapy for intravenous-cannula phlebitis (Dagar 2025). Use for this indication is investigational. It remains a distinct entity from DVT, which is an absolute contraindication to leech application.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan include thrombophlebitis in the list of indications for hirudotherapy[B1].
  • They give an observation by Magomedov: 46 patients with acute thrombophlebitis of the legs; 26 of them, in addition to Aspisol, elevation of the leg and plentiful fluids, received leeches, while 20 patients were given “conventional” treatment; as described, in the group with leeches considerable improvement was noted after the very first sessions — pain, swelling and redness decreased or disappeared[B1].
  • In hospital, according to the text, the main group spent on average 11.1 days, the control group 19.5 days; how the patients were assigned to the groups is not stated in the book[B1].
  • According to the same data, Kutakov (1965), who observed 60 patients with thrombophlebitis of the legs, does not rule out leeches in subacute thrombophlebitis, while the results in the chronic course cannot, in his conclusion, be considered satisfactory; Sidorina (1962) considered the method indicated in acute and subacute thrombophlebitis and of little effect in the chronic form[B1].
  • Michalsen et al. write that in most cases leeches have a markedly positive effect on the course of superficial phlebitis and patients often notice an improvement right away; in the section on evidence they write that after the arrival of heparin hirudotherapy quickly lost much of its former importance but kept a niche use in symptomatic varicose veins and superficial thrombophlebitis, and they give a cautious assessment: years of practice provide much empirical evidence, but little data that meet the criteria of evidence-based medicine[B3].
  • On acute deep vein thrombosis, Michalsen et al. write that leeches as supportive treatment cannot be justified, since the drugs of initial anticoagulation are a contraindication; both books list taking anticoagulants (blood-thinning medicines) among the contraindications, and Flecken and Michalsen call it an absolute one[B1][B3].
  • Michalsen et al. advise against doing hirudotherapy in patients with venous diseases on hot days unless absolutely necessary, and never placing leeches directly on skin with marked inflammation (dermatitis) or ulceration[B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active deep vein thrombosis (acute phase)
  • Critical limb ischemia (ABI <0.4)
  • Deep vein thrombosis (must rule out with duplex)
  • Septic thrombophlebitis (antibiotic therapy primary)
  • Saphenofemoral or saphenopopliteal junction involvement (anticoagulation primary)

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.